BioProtocol unveils OpenLabs platform at DeSci Berlin to merge AI with decentralized research funding
Scientific research funding has a well-known bottleneck problem. Getting a grant through traditional channels can take months, sometimes years, of paperwork, peer review, and institutional gatekeeping. Bio Protocol thinks it has a faster lane.
At DeSci.Berlin 2026 on June 19, the project launched OpenLabs, a platform designed to let researchers turn raw scientific ideas into funded projects using a combination of AI collaboration and community voting. The conference, held at KÖNIG GALERIE as part of Berlin Blockchain Week, has become a recurring launchpad for decentralized science initiatives, with past events spawning projects like Molecule Labs.
What OpenLabs actually does
The platform integrates funding mechanisms directly into its collaborative environment. Researchers can develop projects, coordinate with community members, and secure funding all within a single interface. No bouncing between grant portals, DAO voting dashboards, and separate collaboration tools.
The system pairs human researchers with AI-driven workflows for project development. Community members vote on which projects deserve funding, creating a decentralized alternative to the traditional grant committee model. The BIO token serves as the governance and utility token powering these decisions within Bio Protocol’s broader ecosystem.
Two flagship projects were highlighted at launch. RheumaAI is an AI agent focused on rheumatology research. PeptAI targets peptide discovery.
Bio Protocol’s bigger picture
OpenLabs doesn’t exist in a vacuum. Bio Protocol has positioned itself as financial infrastructure for biotech innovation, using tokenized intellectual property and governance mechanisms called BioDAOs to channel capital toward scientific research.
The project has raised over $33M through its BIO Genesis initiative. The DeSci movement applies blockchain principles to scientific research, including transparent funding trails, community governance over research priorities, and tokenized ownership of intellectual property.
What this means for investors
The BIO token hasn’t shown dramatic price movement in the immediate aftermath of the announcement. For BIO token holders, the governance utility becomes more meaningful as OpenLabs scales, with voting on which scientific projects receive funding representing a more concrete use case than many governance tokens can claim.
The $33M already raised through BIO Genesis gives Bio Protocol runway to iterate on OpenLabs without immediately needing to demonstrate revenue.
The risk that rarely gets discussed in DeSci circles is regulatory. Tokenized intellectual property in biotech sits at an uncomfortable intersection of securities law, patent law, and pharmaceutical regulation. As these projects mature from concept to actual drug discovery pipelines, the legal complexity will only increase.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The AI boom may follow the path of the 19th-century railway bubble, and builders may not be the ultimate winners
Goldman Sachs analyst Bobby Molavi compared the current situation to the 19th-century British railway mania: 500 companies spent more than the nation's annual income building 8,000 miles of railway, with most early investors losing out, while the real beneficiaries were the later "passengers." He pointed out that the current AI craze is driven by both debt and momentum, and that the S&P 500’s forward P/E ratio of 18x is only "a bit cheaper." Whether the builders can retain value is uncertain, and history does not offer an optimistic answer.
If Anthropic's IPO goes smoothly and the stock price rises next week, then everything remains the same for AI. Otherwise, some companies will go bankrupt.
The shrinking valuations of two major giants have triggered a chain reaction—investors are adopting more conservative revenue multiples for AI startups and are directly halting high-valuation financing for companies with zero revenue. Multiple venture capital firms have advised their portfolio companies to lower valuation expectations and to quickly build up cash reserves. Market participants warn that the outcome of Anthropic’s IPO will be a barometer for the industry: if successful, the boom will continue; if it fails, some companies may face elimination.
After the Brazilian election, political discount deepens; Morgan Stanley remains bullish on Petrobras (PBR.US), focusing on fuel pricing and dividends
Morgan Stanley still maintains its most optimistic "Overweight" rating, but has lowered its year-end 2027 target price from $31 to $25.
Corning (GLW.US) receives initial "Buy" rating from Jefferies! AI factories driving a fiber optic rush, with a potential global supply gap of up to 30%
For Corning, the recent profit growth mainly comes from the expansion of AI clusters. As the number of optical links crossing cabinets and campuses increases, customers need to deploy more optical fibers within limited conduit and cabinet space, thus driving demand for high-density optical cables and connection systems.
Crypto prices
More
